Benzinga | Apr 15, 2021 09:17AM EDT

Pulmatrix Hosting Key Opinion Webinar On PUR3100 Therapy For Treatment Of Acute Migraine

Pulmatrix, Inc. (NASDAQ:PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE(tm) technology, today announced that it will host a key opinion leader (KOL) webinar on PUR3100, Pulmatrix's orally inhaled dihydroergotamine (DHE) therapy for the treatment of acute migraine, on Friday, April 23, 2021 at 10:00am Eastern Time.